Liu Na, Zhao Chunhua, Li Dan, Liu Siqi, Sun Hongyan
Department of Breast, Electric Power Hospital, Beijing, 100073, People's Republic of China.
Nursing Department, Electric Power Hospital, Beijing, 100073, People's Republic of China.
Int J Womens Health. 2024 Dec 20;16:2231-2238. doi: 10.2147/IJWH.S481845. eCollection 2024.
To summarise the therapeutic effects of symptomatic nursing during DS-8201 (Enhertu) treatment in a patient with advanced breast cancer with metastases to the ribs, lungs and liver. The patient, diagnosed with breast cancer with multiple metastases, was admitted to the hospital on 4 January 2021, 2 months after the discovery of a right breast mass. DS-8201 was administered during this period, and nursing care was tailored to address the patient's symptoms while on the medication. Before treatment, the Hamilton Anxiety Scale score was 22, the Pittsburgh Sleep Quality Index score was 19 and the Insomnia Severity Index score was 24. After treatment, the SAS score decreased to 15, the PSQI score to 12 and the ISI score to 11, indicating improvements in sleep quality and anxiety. Re-examination showed minimal change in left breast nodules compared with previous results, with no additional metastases detected. By the follow-up in September 2023, the patient showed no signs of obvious recurrence and had not returned to the hospital for further consultation. During a telephone follow-up in October 2023, the patient reported no significant discomfort, her condition remained stable and her health indicators were well controlled while on the medication. This study details the symptoms and corresponding nursing interventions for patients with advanced breast cancer undergoing DS-8201 treatment, providing a nursing reference for future patient care.
总结DS-8201(Enhertu)治疗晚期乳腺癌伴肋骨、肺和肝转移患者时对症护理的治疗效果。该患者被诊断为乳腺癌伴多发转移,于2021年1月4日因发现右乳肿块2个月后入院。在此期间给予DS-8201治疗,并根据患者用药期间的症状进行针对性护理。治疗前,汉密尔顿焦虑量表评分为22分,匹兹堡睡眠质量指数评分为19分,失眠严重程度指数评分为24分。治疗后,SAS评分降至15分,PSQI评分降至12分,ISI评分降至11分,表明睡眠质量和焦虑状况有所改善。复查显示左乳结节与之前结果相比变化极小,未发现新增转移灶。截至2023年9月随访时,患者无明显复发迹象,未回院进一步复诊。在2023年10月的电话随访中,患者报告无明显不适,病情保持稳定,用药期间健康指标得到良好控制。本研究详细介绍了晚期乳腺癌患者接受DS-8201治疗时的症状及相应护理干预措施,为今后的患者护理提供了护理参考。